Diverging Views Shape the Investment Outlook for Replimune

Replimune's stock faces mixed analyst ratings amid clinical trial focus. Q4 2025 loss beats estimates, but FY outlook unchanged. Price targets range from bearish to highly bullish.

For investors in the biotechnology sector, Replimune continues to present a compelling yet uncertain narrative. The company's progress in clinical development is being met with a distinct lack of consensus among market experts regarding its near-term valuation. The stock is currently navigating a landscape marked by conflicting analyst recommendations, searching for a definitive trend.

Financial Metrics and Market Position

Replimune's latest quarterly report, covering the fourth quarter of fiscal 2025, delivered a modest positive surprise. The company posted a loss per share of $0.77, outperforming the average analyst estimate which had anticipated a loss of $0.85. However, projections for the full current fiscal year remain unchanged, with a forecasted loss per share of $2.97.

With a market capitalization of approximately $622.6 million, the firm faces the classic challenge of a research-focused biotech: maintaining a delicate balance between the substantial capital required for research and development and the successful achievement of critical clinical milestones. Institutional investors are closely monitoring management's efficiency in controlling cash burn.

A Spectrum of Analyst Opinions

The analyst community is actively engaged, with ten firms currently providing coverage. Their views, however, are far from uniform. Six experts advocate a "Buy" position, while two recommend "Hold" and another two advise "Sell." This split underscores the differing assessments of the company's clinical pipeline and financial resilience.

The average 12-month price target stands at $10.00, representing a significant premium to the recent closing price of $7.22 on March 27, 2026. Yet within this average lies a wide dispersion of outlooks. Piper Sandler maintains a target of $14.00, while Wedbush presents an even more bullish case with a $19.00 target. In stark contrast, Weiss Ratings sustains a clear "Sell" recommendation.

Clinical Progress as the Key Driver

Operating in the competitive fields of oncology and immunotherapy, Replimune's future stock performance is expected to be predominantly driven by advancements in its clinical trials. Market observers are focusing intently on upcoming data readouts, which are likely to validate or challenge the current range of price targets. The company's ability to demonstrate clinical efficacy will be the ultimate determinant of its valuation trajectory.